

From: Maruna, Thomas
Sent: Monday, February 22, 2016 12:47 PM
To: 'Angela.Azzara@csllbehring.com'; KevinDarryl.White@csllbehring.com
Subject: Revised Draft Label - BLA 125591.0 - Please Respond by
February 29, 2016
Attachments: labeling-draft text.doc

CSL Behring Recombinant Facility AG
Attention: Mr. Kevin Darryl White
February 22, 2016
Sent by email

Dear Mr. White:
We are reviewing your May 29, 2015 biologics license application (BLA)
for the following:

STN	Name of Biological Products
125591/0	Antihemophilic Factor
(Recombinant), Single Chain	

To expedite our review of the Afstylia label, please review all
appropriate sections of the
submitted draft label to reflect the final pediatric data as submitted in
the final study report for
CSL627-3002, the pediatric trial, and submit a revised draft label via
amendment to the BLA.

The review of this submission is on-going and issues may be added,
expanded upon, or modified
as we continue to review this submission.
Please submit your responses as an amendment to this file by February 29,
2016 referencing the
date of this request.
The action due date for this file is May 28, 2016.
If you have any questions, please contact me.
Very Respectfully,

Thomas J. Maruna, MSc, MLS(ASCP), CPH
Lieutenant, U.S. Public Health Service
Senior Regulatory Management Officer
Food and Drug Administration
Center for Biologics Evaluation and Research
Office of Blood Research and Review
10903 New Hampshire Ave.
Silver Spring, MD 20993
thomas.maruna@fda.hhs.gov
O: (240) 402-8454
www.usphs.gov

"THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE
USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN
INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM
DISCLOSURE UNDER LAW. If you are not the addressee, or a person
authorized to deliver the

document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.